Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spruce Biosciences (SPRB) Research & Development (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Research & Development for 4 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 80.87% to $4.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.5 million through Dec 2025, down 57.94% year-over-year, with the annual reading at $19.5 million for FY2025, 57.94% down from the prior year.
  • Research & Development for Q4 2025 was $4.1 million at Spruce Biosciences, down from $5.0 million in the prior quarter.
  • The five-year high for Research & Development was $21.5 million in Q4 2024, with the low at -$430000.0 in Q2 2025.
  • Average Research & Development over 4 years is $9.4 million, with a median of $8.9 million recorded in 2022.
  • The sharpest move saw Research & Development skyrocketed 93.31% in 2024, then plummeted 105.32% in 2025.
  • Over 4 years, Research & Development stood at $8.8 million in 2022, then rose by 25.58% to $11.1 million in 2023, then surged by 93.31% to $21.5 million in 2024, then tumbled by 80.87% to $4.1 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $4.1 million, $5.0 million, and -$430000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.